A geriatrician's insight into reducing the burden of disease in older adults
Who is at an increased risk of adverse effects from an RSV infection? What is the burden of disease and what should be done to alleviate the risk and increase awareness?
Research explores possible link between type 1 diabetes and COVID-19
A trio of new studies from the United States and Europe explore a possible link between COVID-19 and new-onset type 1 diabetes (T1D) in children.
Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination
Global influenza circulation has been heavily suppressed by public health measures and travel restrictions since the onset of the COVID-19 pandemic.
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
These new subvariants carrying further mutations in their spike proteins raise concerns that they may further evade neutralizing antibodies.
Spotlight on the burden of flu for people living with diabetes
Why are people with diabetes more at risk from flu? What are the options for reducing the risk? What are the challenges and solutions to increase awareness across health care professionals, researchers and patients themselves?
Association of COVID-19 with New-Onset Alzheimer’s Disease
An infectious etiology of Alzheimer’s disease has been postulated for decades. It remains unknown whether SARS-CoV-2 viral infection is associated with increased risk for Alzheimer’s disease.
Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission
SARS-CoV-2 is primarily an airborne infection of the upper respiratory tract, which on reaching the lungs causes the severe acute respiratory disease, COVID-19.
Project FluCov: understanding and communicating the impact of COVID-19 on influenza activity
Nivel is researching the impact of COVID-19 on Influenza activity combining data from around the world.
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).
Scientific Papers
Article
Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study
COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection